Home Featured Page 117

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

COMPASS Pathways plc to announce first quarter 2023 financial results on...

The Top 5 Psychedelic Clinical Trials of 2022

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Psychedelics, The Brain, and the Future of Mental Health

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine)...

atai Life Sciences to Participate in Upcoming May Investor Conference

PT408 – Fireside Project: Harm Reduction Through Free Peer Support

American Medical Association to Issue First New Code for Psychedelic Therapies

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

COMPASS Pathways plc to announce first quarter 2023 financial results on...

The Top 5 Psychedelic Clinical Trials of 2022

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Psychedelics, The Brain, and the Future of Mental Health

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine)...

atai Life Sciences to Participate in Upcoming May Investor Conference

PT408 – Fireside Project: Harm Reduction Through Free Peer Support

American Medical Association to Issue First New Code for Psychedelic Therapies

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY